107 related articles for article (PubMed ID: 9664877)
1. The clinical significance of c-myc oncogene expression in melanomas of the scalp.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877
[TBL] [Abstract][Full Text] [Related]
2. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
4. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma.
Ramsden AJ; Grover R; Chana J; Tulley P; Sanders R; Wilson GD
J Plast Reconstr Aesthet Surg; 2007; 60(6):626-30. PubMed ID: 17485049
[TBL] [Abstract][Full Text] [Related]
5. Use of oncogene expression as an independent prognostic marker for primary melanoma.
Grover R; Pacifico MD; Wilson GD; Sanders R
Ann Plast Surg; 2003 Feb; 50(2):183-7. PubMed ID: 12567057
[TBL] [Abstract][Full Text] [Related]
6. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
7. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes.
Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O
Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481
[TBL] [Abstract][Full Text] [Related]
8. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the prognostic significance of the site of origin of cutaneous melanoma.
Law MM; Wong JH
Am Surg; 1994 May; 60(5):362-6. PubMed ID: 8161088
[TBL] [Abstract][Full Text] [Related]
10. Inverse correlation between expression of HLA-B and c-myc in uveal melanoma.
Blom DJ; Mooy CM; Luyten GP; Kerkvliet S; Ouwerkerk I; Zwinderman AH; Schrier PI; Jager MJ
J Pathol; 1997 Jan; 181(1):75-9. PubMed ID: 9072006
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma.
Mooy CM; Luyten GP; de Jong PT; Luider TM; Stijnen T; van de Ham F; van Vroonhoven CC; Bosman FT
Am J Pathol; 1995 Oct; 147(4):1097-104. PubMed ID: 7573354
[TBL] [Abstract][Full Text] [Related]
12. An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 2000 Jan; 53(1):46-50. PubMed ID: 10657449
[TBL] [Abstract][Full Text] [Related]
13. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
[TBL] [Abstract][Full Text] [Related]
14. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy.
Pearl RA; Pacifico MD; Richman PI; Wilson GD; Grover R
J Plast Reconstr Aesthet Surg; 2008; 61(3):265-71. PubMed ID: 17569608
[TBL] [Abstract][Full Text] [Related]
15. The prognostic importance of c-myc oncogene expression in head and neck melanoma.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Ann Plast Surg; 2001 Aug; 47(2):172-7. PubMed ID: 11506326
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of oncogene expression in subungual melanoma.
Grover R; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1997 Jan; 50(1):15-9. PubMed ID: 9038509
[TBL] [Abstract][Full Text] [Related]
17. Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma.
Ross DA; Laing JH; Sanders R; Wilson GD
Eur J Surg Oncol; 2006 Feb; 32(1):80-4. PubMed ID: 16256294
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
20. Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions.
Korabiowska M; Brinck U; Mirecka J; Kellner S; Marx D; Schauer A
In Vivo; 1995; 9(5):433-8. PubMed ID: 8900920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
